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Abstract The 6 selectivity and antagonism of peptides contain- 
ing L-tetrahydro-3-isoquinoline carboxylic acid (Tic) in second 
position can be attributed mainly to the Tyr-Tic unit. These 
properties can be further enhanced by substituting Tyr t with 
2,6-dimethyi-L-tyrosyl (Dmt). Dmt-Tic-NH2, Dmt-Tic-OH, 
Dmt-Tic-Ala-NH2 and Dmt-Tic-Ala-OH are all more active and/ 
or selective than the corresponding [Tyrt]-parent peptides. In fact 
the selectivities of Dmt-Tic-OH and Dmt-Tic-Ala-OH are the 
highest ever recorded for opioid molecules, tH NMR spectra in 
a DMSOIwater mixture at 278 K reveal the presence of two 
similar conformers, characterised by a cis or trans Dmt-Tic bond, 
in all four peptides. A detailed conformational nalysis in solution 
of Dmt-Tic-NH 2 shows that these conformers have a shape very 
similar to that of the bioactive conformation of Tyr-Tic-NH~ and 
to that of naltrindole. 
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1. Introduction 
Several peptides containing L-l,2,3.4-tetrahydroisoquino- 
line-3-carboxylic acid (commonly dubbed Tic) in the second 
position behave as &selective opioid antagonists [I 4 ] ,  whereas 
those beginning with the amino-terminal Tyr-D-Tic-Phe- unit 
are # agonists, as expected [1]. For instance, enkephalin (a 
non-selective agonist) and dermorphin (a # selective agonist) 
are both converted into 6 selective antagonists [2] when their 
second residue is substituted with Tic. The surprising change 
of selectivity induced by the change of chirality in peptides 
containing the tetrahydro-3-isoquinoline carboxylic acid {Tic) 
in second position, originally interpreted [1] as a conforma- 
tional preference induced on the Tyr-Xaa-Phe domain, can be 
*Corresponding author. Fax: (39i (811 552-7771. 
Abbreviations: DMSOa,, perdeuterated dilnethylsulfoxide: Dmt. 2,6- 
dimethyl-L-tyrosyl: DQF-COSY, double-quantum filtered correlation 
spectroscopy: GPI, guinea pig ileum: MVD, mouse vas deferens: 
MeNTI, methylnaltrindole: NM R. nuclear magnetic resonance: NOE, 
nuclear Overhauser ffect: ROESY, rotating frame nuclear Overhauser 
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acid; TIP, Tyr-Tic-Phe-NH2: TIPR Tyr-Tic-Phe-Phe-NH2: TOCSY, 
total correlation spectroscopy: NOESY. nuclear Overhauser effect 
spectroscopy. 
attributed to the Tyr-Tic segment. In our view, this is an indi- 
cation that the N-terminal Tyr-Tic sequence behaves as an 
effective recognition site, i.e. a sort of 'message domain' [5,6] 
for 6 selective antagonism. In fact, even the simple Tyr-Tic-NH2 
and Tyr-Tic-OH dipeptides behave as a 6 selective antagonists 
[4]. This interpretation has been recently confirmed by an inde- 
pendent study on tri- and tetra-peptides containing the amino- 
terminal Tyr-Tic- unit [7]. On the other hand, our di- and 
tl-i-peptides, while endowed of 6 selectivities comparable to 
those of TIP (Tyr-Tic-Phe-NH2) and TIPP (Tyr-Tic-Phe-Phe- 
NH2), have substantially lower affinity and antagonist poten- 
cies than TIP and TIPP [l]; so that it is difficult to determine 
whether the major contribution to antagonism comes from a 
Tyr-Tic- recognition site or from the well known Tyr-Xaa-Phe- 
message domain. 
In order to clarify this issue we have synthesised peptides 
htcking either Phe 3 or Phe 4 but endowed with greater antagonist 
activity and/or 6 selectivity than TIP or TIPR The decisive lead 
ill the design of these new peptides was furnished by the in- 
crease of activity [8-11] shown by peptides in which Tyr ~ is 
substituted by 2,6-dimethyl tyrosine (Dmt). The [Dmtl]-ana - 
logucs of the quoted di- and tri-peptide antagonists [4] did 
prove extremely 6 selective antagonists [12]. Here we present 
a detailed conformational nalysis in solution of Dmt-Tic-NH> 
in comparison with the conformational state of Dmt-Tic-OH, 
Dmt-Tic-Ala-NH2 and Dmt-Tic-Ala-OH. 
2. Materials and methods 
Syntheses and biological assays were performed as described in [12]. 
Energy calculations were based on the all atoms parametrization f
the AMBER force field (as implemented in the SYBYL package) 
[13.141. 
NMR measurements. NMR samples were prepared by dissolving 
appropriate amounts of each peptide in 0.5 ml of 90/10 (v: v) DMSOdJ 
H,O cryoprotective mixture to make 2 mM solutions. NMR spectra 
were run at 400 MHz on a Bruker AM-400 instrument equipped with 
an Aspect 3000 computer and at 500 MHz on a Bruker AMX-500 
instrument equipped with an X-32 computer. DQF-COSY [15], 
TOCSY [16], NOESY [17] and ROESY [18] experiments were run in 
the phase-sensitive mode using quadrature detection in o) 1 by time- 
proportional phase incrementation of the initial pulse [19]. NOESY 
spectra were run at different mixing times (75, 150, 200 and 300 ms) to 
check the possible presence of spin diffusion and to better calibrate the 
interproton distances extracted from cross-peak volumes. Distance 
constraints were derived from the NOESY spectrum recorded with a 
75 ms mixing time, using the method of Esposito and Pastore [20] after 
correction for spin diffusion according to the method of Majumdar and 
Hosur [21]. Relative scaling of the constraints was achieved by using 
a value of 1,79 A for the distance between theft geminal protons 4 and 
4' of the Tic side chain. 
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Table 1 
Binding properties and pharmacological characterization f peptides containing the Tyr-Tic ~ and Dmt-Tic b message domains 
K i /d Ki ~5 K i ll/K~ 6 GPI MVD pA 2 
(nM) (nM) IC5o (nM) IC5o (nM) 
Tyr-L-Tic-NH: 28,70(} 
Dmt-L-Tic-NH2 280 
Tyr-L-Tic-OH 28,400 
Dmt-L-Tic-OH 3,300 
Tyr-L-Tic-Ala-N H2 33.800 
Dmt-L-Tic-Ala-NH 2 47 
Tyr-L-Tic-Ala-OH 8.300 
Dmt-L-Tic-Ala-OH 5,800 
TIP c 
TIPP ~ 
Naltrindole L 
170 170 > 104 > 104 (ant) 6.0 
i .22 230 7.2 
190 150 > 104 > 104 (ant) 
0.022 150,000 8.2 
55 610 > 104 > 104 (ant) 6.2 
0.24 195 8.5 
56 150 > 107 > 10 4 (ant) 7.0 
0.28 21,000 8.4 
141 7.9 
1410 8.5 
18 9.2 
"Data from [4]. 
bData from [12]. 
~Data adapted from [1]. 
3. Results and discussion 
Table 1 summarises the pharmacological properties of Dmt- 
Tic-NH 2, Dmt-Tic-OH, Dmt-Tic-Ala-NH 2 and Dmt-Tic-Ala- 
OH together with those of the corresponding peptides contain- 
ing the Tyr-Tic 'message' [4]. The affinities for both/~ and ~; 
receptors of [Dmt']-peptides are in all cases significantly higher 
than those of the corresponding [Tyr~]-peptides. ~; selectivity is 
only slightly changed for the two amides, as expected from 
literature data on other [Dmd]-peptides [7-10], but increases 
enormously for the two peptides with a free carboxyl C-termi- 
nal. It is worth emphasising that although the pA2's of Dmt- 
Tic-OH (8.2) and Dmt-Tic-Ala-OH (8.4) are comparable to 
those of TIPP (8.5) and naltrindole (9.2), their/~/~ selectivities 
@ c 
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Fig. 1. Schematic formula of Dmt-l -Tic-NH, with numbering of the protons of the Tic side chain (top). Molecular models of the two conformers 
of Dmt-Tic-NH, observed in solution (c/T/T and t/T/T; bottom). 
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Fig. 2. Best fit of the two prevailing conformers of Omt-Tic-NH2 (c/T/T and dT/TI and of the minimum energycis conformer of Dmt-Tic-Ala-NH 2 
with MeNTI: MeNTI is shown as space-filling model. 
are one to four orders of magnitude higher (150,000 and 21,000 
vs. 1410 and 18, respectively). The increase of selectivity found 
for Dmt-Tic-OH and Dmt-Tic-Ala-OH with respect o Dmt- 
Tic-NH2 and Dmt-Tic-Ala-NH, is consistent with Schwyzer's 
hypothesis on the role of charges [5,6] for receptor selection but 
is so large that it may reflect conformational changes or specific 
receptor interactions as well. 
In order to investigate he role of conformation i determin- 
ing the affinities and selectivities of Table 1 we undertook a ~H 
NMR study in solution. The ~H NMR spectra of all four 
[Dmt~]-peptides, in DMSO or in a 90/10 (v:v) DMSOdJH_,O 
cryoprotective mixture, are characterised by the presence of 
two stable conformers which have similar NMR parameters t\~r 
the two initial residues common to all peptides, indicating that 
the conformations, in each peptide, are dominated by the con- 
formational preferences of the Dmt-Tic moiety. Accordingl}, 
we chose to investigate he conformations of Dmt-Tic-NH~ in 
greater detail since, on the basis of the NMR data, they are also 
representative of the corresponding conformers of the other 
peptides. 
NOESY and ROESY spectra of Dmt-Tic-NH2 in DMSOd6 
at room temperature show a very large number of cross-peaks 
for a peptide of this size. Notwithstanding, to make a homoge- 
neous comparison with the solution study of Tyr-Tic-NH> we 
ran all quantitative experiments in a 90110 (v:v) DMSOa6/H20 
cryoprotective mixture [2] at 278 K. In fact, we have shown that 
the use of biocompatible media with viscosities of the order of 
7 10 cp, not only leads to a quantitative increase of all NOEs 
observed at lower viscosity, as expected by the theory of micro- 
viscosity, but also to selective growth of (conformationally di-
agnostic) effects involving backbone protons with respect o 
intrachain ones [22]. 
The NOESY spectrum of Dmt-Tic-NH2 in the 90/10 (v:v) 
DMSOdJH:O cryoprotective mixture at 278 K contains two 
subspectra corresponding to two conformers, or families of 
conformers, arising from the cis/trans isomerism around the 
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Fig. 3. Best fit of the two prevailing conformers ofDmt-Tic-NH2 (dT/T 
and t/TIT) with the model of conformer CIb + f of Tyr-L-Tic-NH> 
Clb + f is shown as space-filling model. 
Dmt-Tic bond. The relative populations of the two conformers 
A and B are 0.75 and 0.25, respectively. The assignment of A 
and B to cis/trans families was made through diagnostic NOEs: 
the C~-C~ effect characteristic of a cis Dmt-Tic bond was ob- 
served in the subspectrum of A, whereas that of B shows a cross 
peak between the Dmt C~ and the Tic 1, 1' protons character- 
istic of a trans Dmt-Tic bond [see Fig. 1 for numbering). 
Isomers A and B can differ in the conformations of the two 
side chains but their identification is simplified by the experi- 
mental observation that the aliphatic moiety of the Tic ring has 
the same conformation i both isomers. In fact, the J~o/J~,o, 
coupling constants have pairs of values for all isomers that are 
only consistent with a half-chair conformation very similar to 
that observed for Tyr-Tic-NH 2 [2,4]: 3.5/5.3 and 3.8/5.9 for A 
and B, respectively (all measured in Hz). Thus, isomers A and 
B can only differ in ~l, ,~fl and Z2 values. 
In order to facilitate the interpretation f the NMR data we 
undertook an exhaustive conformational search of Dmt-Tic- 
NH2 by holding the peptide bond trans for B and cis for A, the 
ring conformation ofTic fixed in a half-chair conformation and 
varying ~,  Z~ and Z2 systematically in steps of 15 °. All mini- 
mum energy conformers have similar values of Z2 (of the order 
of 90°): therefore, in the following, isomers will be symbolically 
designated by a c (for cis) or a t (for trans) followed by the 
values of gq, Z1 closest o 180 ° (7"), 60 ° (G-) or -60 ° (G+). 
This conformational nalysis yields 14 low energy conform- 
ers within a range of 20 kcal/mol from the absolute nergy 
minimum corresponding to conformer (c/T/T), six with a cis 
and eight with a trans peptide bond. Among the six cis conform- 
ers of relative minimum energy, only (c/TIT), the absolute min- 
imum, is fully consistent with the NMR parameters of A. The 
NMR data that characterise A molecules are the pronounced 
upfield shifts of the resonances of the a, fl and fl' protons of Tic 
and the concomitant NOEs of Tic Ha with both 2 and 6 methyl 
groups and with Tic 1. It can be seen from the molecular model 
of Fig. 1 that the ring of Dmt can induce prominent ring- 
current shifts on the ~, fl and fl' protons of Tic to account for 
their upfield resonances whereas the diagnostic NOEs between 
Tic H~ with methyl groups and with Tic 1 do correspond to 
short distances in the model. Similar considerations lead to the 
assignment of B to conformer (tIT~T) whose energy is 2.97 
kcal/mol above that of (c/T/T). The spectra of the other pep- 
tides can be interpreted in terms of very similar conformers, as 
far as the Dmt-Tic moiety is concerned, with small quantitative 
differences due to the influence of the C-terminal part. The 
molecular models of the two minimum energy (cis and trans) 
conformers of Dmt-Tic-NH2 are reported in Fig. 1 along with 
the scheme of the molecule indicating the numbering of the 
protons of the Tic side chain. In spite of the different configu- 
ration of the peptide bond, both conformers (i.e. c/T/T and 
t/T/T) have a similar compact shape reminiscent of that of the 
conformer of Tyr-Tic-NH 2 (Clb + f) that we proposed as the 
bioactive conformation of that antagonist [2,4]. 
These models can now be used for comparison with confor- 
mationally rigid d selective opiates to test their consistency with 
the hypothetical bioactive conformation. There are several nal- 
trindole derivatives with a fairly good ~ selectivity, both ag- 
onists and antagonists. For consistency with previous work on 
antagonists [2,4] we selected once again N-methyl naltrindole 
(MeNTI) as a typical rigid d antagonist [23]. Superpositions 
with the models of our peptides were generated by overlaying 
only a portion of the tyramine moiety of the peptides with the 
corresponding atoms of MeNTI: N, C~, C~ and the C-1 and C-4 
carbons of the aromatic ring. In fact, it must be noted that the 
ortho and meta carbon atoms of the aromatic ring of Tyr (or 
Dmt of any opioid peptide) cannot possibly overlap with the 
corresponding atoms of any alkaloid related to morphine since 
the orientation of the ring depending from thez2 torsion angle 
is forced by cyclization (in all alkaloids) to values close to 0 ° 
that are energetically inaccessible in linear molecules. It can be 
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seen from Fig. 2 that both conformers of Dmt-Tic-NH, are 
consistent with the shape of this rigid non-peptidic agonist. As 
anticipated in the presentation of the NMR data, the preferred 
conformations of the other [Dmt-Tic-] peptides are very similar 
to those found for Dmt-Tic-NH2, i.e. (c/T/T) and (t/T/T). As 
an example, Fig. 2 shows also the fit of the minimum energy 
cis conformer of Dmt-Tic-Ala-NH, with MeNTI; it can be seen 
that the N-terminal Dmt-Tic- moiety has almost exactly the 
same fit as in conformer (c/T/T) of Dmt-Tic-NH,. 
Fig. 3 shows a comparison of conformers (c/T/T) and (t /T/T) 
with the molecular models of conformer C lb  + for Tyr-Tic- 
NH2. It can be appreciated that they are very similar, in partic- 
ular, all the corresponding atoms of (c/T/T) and C lb  + f are 
coincident, with a RMS error of 0.18/~ in the overlay. These 
findings lead strong support o our proposal [2,4] that the 90 ° 
arrangement of the two aromatic rings of conformer C lb  + f 
is consistent with specific 8 receptor equirements. In fact, all 
the peptide models of Fig. 3 are consistent with the shape of 
the rigid ~ selective antagonist MeNTI [4,23,24]. 
It is also noteworthy that both (c/T/T) and (t/TIT), which 
account for all conformers of Dmt-Tic-N H 2, are consistent with 
receptor requirements whereas, in the case of Tyr-Tic-NH2, 
conformer C lb  + f, the only low-energy conformer consistent 
with the shape of MeNTI, represented only 40% of all solution 
conformations. Yet, the increase of relative populations of bio- 
active conformers observed in solution is not sufficient per se 
to explain the high affinity and selectivity of the [Dmt~]-pep- 
tides. The increased 6 selectivity observed when the C-terminal 
amides are changed into carboxyl groups is consistent with the 
role of negative charges in the membrane-assisted r ceptor- 
selection [5,6] but is too large to be fully accounted for. It seems 
probable that the two methyl groups of Dmt, while favouring 
a better fit of the tyramine moiety in the T subsite [25,26] of 
both receptors, impose more severe constraints on the interac- 
tion of the whole molecule with its receptor. In other words. 
[DmtL]-peptides are only slightly more rigid in solution but 
much more rigid inside the receptors, e.g. the good fit of Dmt 
might force the carboxyl groups of Dmt-Tic-OH and Dmt-Tic- 
AIa-OH to come into close contact with the anionic site of p 
receptors. It is somewhat surprising that our peptides are much 
more selective than naltrindole. Such a behaviour may reflect 
mutual adaptability of antagonists and receptors. That is, our 
(relatively flexible) peptides can fit only the ~ receptor directly 
without he need for energetically difficult conformational tran- 
sitions, whereas the rigid naltrindole may force the/l  receptor 
to adapt to its shape. 
At any rate it seems lair to conclude that the bioactive con- 
formation is the same for [Tyrl-Tic]-peptides and [DmtLTic] -
peptides, with a recognition site I'message domain') confined 
to the first two residues. The presence, in [Tic2]-peptide antag- 
onists, of Phe ~ and/or Phe 4 [1,27] may further stabilise the 
bioactive conformation (of the first two residues) or introduce 
additional bioactive conformations (with Tyr-Tic-Phe- as "mes- 
sage') but is by no means necessary to determine antagonism 
.4cknowledgernents: We thank Dr. J.H. Digos of Searle for a sample of 
Dmt. 
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